Page URL:

Nerve stem cell trial for brain disorder planned

10 March 2006
By BioNews
Appeared in BioNews 349

US researchers are set to test a fetal nerve stem cell treatment for Batten disease, a rare and currently incurable genetic brain disorder. Oregon Health and Science University (OHSU) says the trial aims to test the safety of the approach, since transplants of purified nerve stem cells have never been carried out in patients before. The cells are produced by the Californian firm StemCells Inc, which received approval from the Food and Drug Administration (FDA) for the treatment last October. Now, OHSU's Institutional Review Board has given the go-head for the first trial to begin.

Batten disease refers to a group of genetic conditions called Neuronal Ceroid Lipofuscinoses (NCLs), which cause mental impairment, worsening seizures and progressive loss of sight and movement. Affected children gradually become blind, bedridden and unable to communicate. There are four main types of this severe life-limiting disorder: a juvenile form that first appears between the ages of 5-8, two that begin earlier in childhood and a very rare form that affects adults.

The disease is caused by one of several different faulty genes, all of which make proteins that usually break down harmful substances in the cell. In people with NCL disorders, one of these 'lysosomal enzymes' is missing or not working properly, which leads to a build-up of substances called lipopigments in the body's tissues. Eventually, this build-up triggers the death of nerve cells in the brain, retina and central nervous system. Robert Steiner, who is leading the study - along with surgeon Nathan Seldon - says that NCL is 'a heartbreaking and devastating diagnosis for children and their families'. He said that previous research on fetal nerve cell transplants in animals has showed promise, but stressed that 'to our knowledge' such transplants have never been carried out in people before. 'It is our hope that stem cells will provide an important therapeutic advance for these children who have no other viable options', he added.

The trial will test the suitability of the treatment for patients with the infantile and late-infantile forms of NCL, but not the juvenile or adult forms of the disorder. The children will receive injections of the stem cells directly into their brains, and will be followed up for at least four years. In this way, the scientists hope to gain some initial results on whether the treatment can slow the progression of the disease, as well as its safety.

Other ongoing trials are testing the effectiveness of fetal cell transplants for brain disorders such as Parkinson's and Huntington's disease. 'Delivering the benefits of stem cell technology directly into the human brain will, in my opinion, be a major step forward in the efforts of scientists and clinicians around the country to find new treatments with the potential to help tens of thousands of patients with degenerative brain diseases', Dr Seldon said in a press release.

Researchers to Begin Brain Stem Cell Trial
The Washington Post |  9 March 2006
StemCells, Inc. Receives IRB Approval From Oregon Health & Science University To Begin Phase I Clinical Trial In Batten Disease; First Ever Clinical Trial Using Purified Human Neural Stem Cells
Business Wire |  9 March 2006
6 February 2012 - by Ruth Retassie 
US company StemCells Inc have received Food and Drug Administration (FDA) authorisation to carry out clinical trials of their treatment for one of the leading causes of blindness in over 55-year-olds...
2 October 2006 - by Laura Goodall 
The first trial for a proposed stem cell treatment for Batten's disease is about to begin. Researchers at the Oregon Health and Science University's (OHSU) Doernbecher Children's Hospital, US, plan to treat six children with the rare neurodegenerative disorder by using fetal stem cell transplants. Children with...
27 February 2006 - by BioNews 
The latest results from a trial in which five Huntington's disease (HD) patients received fetal nerve tissue transplants show that the treatment can slow, but not stop the progression of the condition. The study, carried out at the Henri Mondor Hospital in France, shows that for some patients, cell transplants...
10 January 2005 - by BioNews 
A Japanese team of researchers has used embryonic stem cells to successfully repair the brain damage caused by Parkinson's disease in monkeys. The team, based at Kyoto University, used monkey embryo stem cells to produce nerve cells, which they transplanted into the brains of monkeys affected by a primate model...
5 July 2004 - by BioNews 
In the first experiment of its kind, researchers used human stem cells to treat rats affected by symptoms of Parkinson's disease. The results are promising, with a reduction in symptoms and the absence of side-effects experienced by other studies. The researchers, from Hadassah University hospital, Jerusalem, grew cloned human embryonic...
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.